Atlas Trials

iCell Gene Therapeutics

17 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch iCell Gene Therapeutics

RecordFirmDate
BCMA-CD19 cCAR T for the Treatment of Refractory Lupus (NCT07328581)iCell Gene Therapeutics2026-01-01
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy (NCT07715136)iCell Gene Therapeutics2025-03-20
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases (NCT06787989)iCell Gene Therapeutics2024-08-31
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma (NCT05212584)iCell Gene Therapeutics2022-07-01
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia (NCT05445765)iCell Gene Therapeutics2022-07-01
BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) (NCT05474885)iCell Gene Therapeutics2022-04-01
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances (NCT04934774)iCell Gene Therapeutics2020-12-01
CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies (NCT04162340)iCell Gene Therapeutics2019-07-11
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma (NCT04162353)iCell Gene Therapeutics2019-07-01
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma (NCT04156269)iCell Gene Therapeutics2018-08-31
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies (NCT04156178)iCell Gene Therapeutics2018-08-01
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT03795779)iCell Gene Therapeutics2018-03-01
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT04156256)iCell Gene Therapeutics2018-03-01
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies (NCT04156243)iCell Gene Therapeutics2018-02-01

Track iCell Gene Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.